
pm et
summari engag discoveri develop commerci treatment
infect respiratori disord cardiovascular condit cancer
price-to-earnings oper ep
risk assess reflect gilead abil increas
domin hiv market share off-set slow hepat
 market see opportun oncolog emerg
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
see sale declin
billion follow declin
lower sale hepat hcv drug
lower price shorter treatment durat
hepat hcv patient increas
competit see hcv sale
billion billion hiv
antivir sale rose billion
includ genvoya descovi odefsey
juli receiv fda approv
vosevi treat hcv genotyp
billion
octob acquir kite pharma
billion expand presenc cell
gene-therapi yescarta becam first
adult non-hodgkin lymphoma
fail chemotherapi
fda-approv gene therapi view
approv posit anticip slow
ramp due complic process
potenti sever side effect yescarta
price
see ep
recent lower recommend
share hold buy share price
risen close target price although
anticip continu signific declin
hcv sale share trade
ep estim slightli peer
near fair valu robust free cash flow
billion combin
billion cash invest
flexibl capit deploy also
encourag growth hiv
antivir although simtuzumab
non-alcohol steatohepat nash
discontinu sever
compound posit data readout
current phase trial gs-
phase ii trial recent
posit result within inflamm
partner galapago began phase trial
filgotinib rheumatoid arthriti ulcer
coliti crohn diseas
risk recommend target price
includ larger-than-expect declin hcv
sale pipelin failur
target price
ep estim peer
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview primari area focu includ human immunodefici
viru hiv liver diseas chronic hepat viru hcv infect chronic hepat viru
hbv infect oncolog inflamm seriou cardiovascular respiratori condit
oper approxim countri world-wide
liver diseas area compani receiv approv food drug administr
fda european commiss harvoni decemb first once-daili singl tablet
regimen treatment hcv genotyp infect adult harvoni combin inhibitor
ledipasvir nucleotid analog polymeras inhibitor sofosbuvir approv
tradenam sovaldi
compani evalu tenofovir alafenamid taf treatment hbv complet
enrol phase clinic trial compani also conduct phase clinic studi
tarmogen cell immun stimul oral agonist evalu potenti
cure hbv
compani evalu simtuzumab nonalcohol steatohepat nash phase clinic trial
decemb also enter agreement phenex pharmaceut ag phenex
compani acquir phenex farnesoid receptor fxr program consist small molecul
fxr agonist treatment liver diseas includ nash
hiv area compani submit new drug applic once-daili singl tablet regimen
contain elvitegravir mg cobicistat mg emtricitabin mg taf mg e/c/f/taf
treatment infect adult compani also receiv approv unit state
tybost cobicistat vitekta elvitegravir mg mg compon stribild
compani also advanc research develop pipelin activ clinic studi
approxim phase clinic trial
stribild oral formul dose day treatment infect treatment-na
adult stribild compani third complet singl tablet regimen treatment hiv
fixed-dos combin antiretrovir medic vitekta tybost viread emtriva
emtricitabin stribild approv fda european commiss
complera/eviplera oral formul dose day treatment infect adult
product market unit state complera europ eviplera compani
second complet singl tablet regimen treatment hiv fixed-dos combin
antiretrovir medic viread emtriva janssen non-nucleosid revers transcriptas
atripla oral formul dose day treatment hiv infect adult atripla
compani first singl tablet regimen hiv intend therapi combin
antiretrovir fixed-dos combin compani antiretrovir medic viread
emtriva bristol-my squibb non-nucleosid revers transcriptas inhibitor sustiva efavirenz
truvada emtricitabin tenofovir disoproxil fumar oral formul dose day part
combin therapi treat hiv infect adult fixed-dos combin compani
antiretrovir medic viread emtriva fda also approv truvada combin safer
sex practic reduc risk sexual acquir infect adult high risk strategi call
viread oral formul nucleotid analog revers transcriptas inhibitor dose day
part combin therapi treat hiv infect patient two year age older european
commiss approv use viread combin antiretrovir agent treatment
infect adolesc patient age approxim year nucleosid revers
transcriptas inhibitor resist toxic preclud use first-lin pediatr agent viread
also approv treatment chronic hbv
chief offic
execut chairman
board director
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc februari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
biosimilar drug approv set
exclus brand drug maker see
biosimilar advanc modest rate
next sever year march fda
approv novarti filgrastim biosimilar
sandoz began sell biosimilar
name zarxio septemb april
fda approv inflectra manufactur
celltrion co-market inflectra
biosimilar johnson johnson
remicad began ship inflectra
risk novemb discount
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug note prescript
benefit manag health insur
exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 year date
septemb biotech index
rose vs rise
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci
anticip limit sale growth
mainli due forecast
sale declin
robust growth period
compound annual growth rate think
sale growth somewhat limit
heighten focu high drug price
encourag view strong period
report late-stag clinic
result accommod fda
approv howev fda approv
new drug significantli
robust new drug approv
sinc record approv
think mani newly-approv drug
signific commerci prospect repres
major advanc therapi diseas
cystic fibrosi hepat multipl
sclerosi cancer expect wider
adopt biomark research
genetic-target clinic studi help
late fda introduc
speed develop promis program
expect favor merger acquisit
climat larg pharmaceut firm move
off-set lost revenu expir drug patent
larg biotech bolster drug pipelin
scale acquisit
industri bellweth becam first
biotech compani initi regular dividend
began dividend payment
establish fda author govern
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
research develop dr riva becom member gilead senior
leadership team dr riva join gilead januari senior vice presid
hematolog oncolog therapeut area head instrument
expand gilead oncolog program recent acquisit kite pharma
establish compani leader field cellular therapi also
guid strategi develop gilead broader oncolog pipelin
tenur prior join gilead dr riva serv head global oncolog
develop novarti oversaw develop world-wide
regulatori approv multipl compound varieti tumor type earlier
career work physician treat patient hematolog
malign univers hospit milan
inc announc kevin young cbe chief oper offic
plan retir effect earli mr young remain gilead
first quarter next year advisori capac
et cfra maintain buy opinion share gilead scienc
inc announc sign definit agreement
acquir kite pharma inc kite nr billion per share
cash kite leader emerg field cell therapi use
patient immun system fight cancer deal subject
customari close condit regulatori approv expect close
see deal posit give excit asset
particularli car-t therapi fight cancer kite lead product
axicabtagen ciloleucel expect receiv fda approv nov
et cfra keep buy opinion share gilead scienc
rais target peer
forward ep estim ep vs
ahead estim rais ep estim sale
fell better expect robust hiv sale strong
uptak taf product anticip continu lower hepat sale
encourag new patient start rais sale guidanc
cash believ provid
signific financi flexibl capit deploy /jeffrey loo cfa
analyst research note compani news
inc announc jame meyer execut vice presid
commerci oper retir mr meyer join gilead
region sale director appoint current role
follow brief famili leav earlier year mr meyer made decis
retir full-tim role effect immedi mr meyer remain
compani advisori capac consult prioriti project
assist identifi successor facilit transit
et cfra lower opinion share gilead scienc inc
hold buy keep target
below-p ep estim set ep
ep vs view sale fell
expect antivir product sale includ hiv hepat
hbv hepat hcv drug vs strength hiv
hbv off-set continu declin hcv see continu declin hcv
product sale note strong uptak competit offer like take
market share guid sale mid
inc announc jacquelin barton ph
appoint compani board director previous serv
gilead scientif advisori board serv
board director chemic compani current
member materi scienc advisori committe dowdupont inc
found serv board geneohm scienc inc member
nation academi scienc nation academi medicin
inc announc execut chairman john martin phd
transit current role execut chairman chairman board
director effect march dr martin name execut chairman
march succeed ceo john milligan phd dr
martin serv ceo gilead join compani
vice presid research develop time
ceo built compani portfolio market product annual
revenu billion
keep target well-below-p
forward ep estim ep vs
ahead view sale fell slower hepat sale
forecast encourag posit phase ii trial result
treat nonalcohol steatohepat nash recent
yescarta approv treat non-hodgkin lymphoma anticip slow ramp-up
yescarta need final train certif due
complic process still see blockbust potenti yescarta /jeffrey
et cfra keep buy opinion share gilead scienc
recent acquir kite pharma receiv fda approv
gene-therapi treatment yescarta treat adult non-hodgkin
lymphoma fail chemotherapi second gene therapi
approv fda view approv posit although
anticip slow ramp-up due complic process potenti sever
side-effect believ yescarta receiv approv indic
reach sale yescarta price
norvarti gene therapi treatment kymriah price /jeffrey loo
inc announc promot alessandro riva md
execut vice presid oncolog therapeut respons
gilead hematolog oncolog program includ cell therapi
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
